JP5584393B2 - 動物細胞における多剤耐性を逆転させる方法 - Google Patents

動物細胞における多剤耐性を逆転させる方法 Download PDF

Info

Publication number: JP5584393B2
Authority: JP; Japan
Prior art keywords: protein; adenovirus; promoter; group; nucleic acid
Prior art date: 2004-12-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2007548837A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008526188A (ja

JP2008526188A5 (zh

Inventor

ホルム，ペル・ゾンネ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-31

Filing date

2006-01-02

Publication date

2014-09-03

2006-01-02 Application filed by Individual filed Critical Individual

2008-07-24 Publication of JP2008526188A publication Critical patent/JP2008526188A/ja

2009-02-19 Publication of JP2008526188A5 publication Critical patent/JP2008526188A5/ja

2014-09-03 Application granted granted Critical

2014-09-03 Publication of JP5584393B2 publication Critical patent/JP5584393B2/ja

Status Active legal-status Critical Current

2026-01-02 Anticipated expiration legal-status Critical

Links

230000036457 multidrug resistance Effects 0.000 title claims description 25
238000000034 method Methods 0.000 title description 55
210000004102 animal cell Anatomy 0.000 title description 4
241000701161 unidentified adenovirus Species 0.000 claims description 493
210000004027 cell Anatomy 0.000 claims description 404
108090000623 proteins and genes Proteins 0.000 claims description 375
102000004169 proteins and genes Human genes 0.000 claims description 263
206010028980 Neoplasm Diseases 0.000 claims description 237
150000007523 nucleic acids Chemical class 0.000 claims description 224
102000039446 nucleic acids Human genes 0.000 claims description 186
108020004707 nucleic acids Proteins 0.000 claims description 186
230000014509 gene expression Effects 0.000 claims description 172
230000010076 replication Effects 0.000 claims description 166
101710199711 Early E1A protein Proteins 0.000 claims description 102
239000003795 chemical substances by application Substances 0.000 claims description 87
239000003814 drug Substances 0.000 claims description 80
102000043276 Oncogene Human genes 0.000 claims description 61
229940079593 drug Drugs 0.000 claims description 61
230000002074 deregulated effect Effects 0.000 claims description 60
108700020796 Oncogene Proteins 0.000 claims description 56
239000000824 cytostatic agent Substances 0.000 claims description 49
210000004881 tumor cell Anatomy 0.000 claims description 49
230000022131 cell cycle Effects 0.000 claims description 47
230000001419 dependent effect Effects 0.000 claims description 33
108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
230000005855 radiation Effects 0.000 claims description 29
230000001105 regulatory effect Effects 0.000 claims description 27
239000013543 active substance Substances 0.000 claims description 24
230000001404 mediated effect Effects 0.000 claims description 23
101710114676 E1B 55 kDa protein Proteins 0.000 claims description 21
210000000056 organ Anatomy 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 20
108020004459 Small interfering RNA Proteins 0.000 claims description 18
230000002950 deficient Effects 0.000 claims description 18
230000001085 cytostatic effect Effects 0.000 claims description 17
108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims description 16
108090000765 processed proteins & peptides Proteins 0.000 claims description 16
230000030648 nucleus localization Effects 0.000 claims description 14
108091023037 Aptamer Proteins 0.000 claims description 13
108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 13
230000001939 inductive effect Effects 0.000 claims description 12
108090000695 Cytokines Proteins 0.000 claims description 11
102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 11
230000006907 apoptotic process Effects 0.000 claims description 11
230000007812 deficiency Effects 0.000 claims description 11
230000035945 sensitivity Effects 0.000 claims description 10
102000004127 Cytokines Human genes 0.000 claims description 9
239000004037 angiogenesis inhibitor Substances 0.000 claims description 9
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 9
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 8
102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims description 8
102000053642 Catalytic RNA Human genes 0.000 claims description 8
108090000994 Catalytic RNA Proteins 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
108091092562 ribozyme Proteins 0.000 claims description 8
230000000692 anti-sense effect Effects 0.000 claims description 7
108010057856 Adenovirus E2 Proteins Proteins 0.000 claims description 6
230000001276 controlling effect Effects 0.000 claims description 6
229920001184 polypeptide Polymers 0.000 claims description 5
229940002612 prodrug Drugs 0.000 claims description 5
239000000651 prodrug Substances 0.000 claims description 5
108700026220 vif Genes Proteins 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
108010048626 Y-Box-Binding Protein 1 Proteins 0.000 description 405
102100022224 Y-box-binding protein 1 Human genes 0.000 description 404
241000700605 Viruses Species 0.000 description 312
210000004940 nucleus Anatomy 0.000 description 158
230000037430 deletion Effects 0.000 description 89
238000012217 deletion Methods 0.000 description 89
101150075174 E1B gene Proteins 0.000 description 87
239000013598 vector Substances 0.000 description 67
239000000047 product Substances 0.000 description 66
238000011282 treatment Methods 0.000 description 59
230000003612 virological effect Effects 0.000 description 59
201000011510 cancer Diseases 0.000 description 55
230000006870 function Effects 0.000 description 50
150000001413 amino acids Chemical class 0.000 description 48
208000015181 infectious disease Diseases 0.000 description 46
108700019146 Transgenes Proteins 0.000 description 45
150000001875 compounds Chemical group 0.000 description 42
239000013612 plasmid Substances 0.000 description 39
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 38
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 37
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 37
229960004768 irinotecan Drugs 0.000 description 36
210000001519 tissue Anatomy 0.000 description 35
230000027455 binding Effects 0.000 description 33
108010078791 Carrier Proteins Proteins 0.000 description 32
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 32
230000000694 effects Effects 0.000 description 31
108020004414 DNA Proteins 0.000 description 29
239000002245 particle Substances 0.000 description 29
238000010367 cloning Methods 0.000 description 28
230000009089 cytolysis Effects 0.000 description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
101710155188 Hexon-interlacing protein Proteins 0.000 description 24
241001135569 Human adenovirus 5 Species 0.000 description 24
108700005077 Viral Genes Proteins 0.000 description 24
230000015572 biosynthetic process Effects 0.000 description 24
201000010099 disease Diseases 0.000 description 24
230000029812 viral genome replication Effects 0.000 description 24
239000002609 medium Substances 0.000 description 22
230000001965 increasing effect Effects 0.000 description 21
230000002829 reductive effect Effects 0.000 description 21
230000032258 transport Effects 0.000 description 21
238000013461 design Methods 0.000 description 20
208000026310 Breast neoplasm Diseases 0.000 description 19
108091008819 oncoproteins Proteins 0.000 description 19
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 18
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 18
229960000975 daunorubicin Drugs 0.000 description 18
206010006187 Breast cancer Diseases 0.000 description 17
230000004913 activation Effects 0.000 description 17
208000009956 adenocarcinoma Diseases 0.000 description 17
230000000875 corresponding effect Effects 0.000 description 17
239000002773 nucleotide Substances 0.000 description 17
238000013518 transcription Methods 0.000 description 17
230000035897 transcription Effects 0.000 description 17
201000008808 Fibrosarcoma Diseases 0.000 description 16
239000012634 fragment Substances 0.000 description 16
230000035772 mutation Effects 0.000 description 16
230000025308 nuclear transport Effects 0.000 description 16
239000004055 small Interfering RNA Substances 0.000 description 16
108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
206010060862 Prostate cancer Diseases 0.000 description 15
208000000236 Prostatic Neoplasms Diseases 0.000 description 15
239000003534 dna topoisomerase inhibitor Substances 0.000 description 15
125000003729 nucleotide group Chemical group 0.000 description 15
229940044693 topoisomerase inhibitor Drugs 0.000 description 15
238000004458 analytical method Methods 0.000 description 14
210000003855 cell nucleus Anatomy 0.000 description 14
230000008569 process Effects 0.000 description 14
230000001413 cellular effect Effects 0.000 description 13
238000001415 gene therapy Methods 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
239000000523 sample Substances 0.000 description 13
206010041823 squamous cell carcinoma Diseases 0.000 description 13
230000001225 therapeutic effect Effects 0.000 description 13
238000013519 translation Methods 0.000 description 13
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 12
210000000805 cytoplasm Anatomy 0.000 description 12
229940121372 histone deacetylase inhibitor Drugs 0.000 description 12
239000003276 histone deacetylase inhibitor Substances 0.000 description 12
239000003550 marker Substances 0.000 description 12
201000001441 melanoma Diseases 0.000 description 12
201000008968 osteosarcoma Diseases 0.000 description 12
238000001959 radiotherapy Methods 0.000 description 12
108091008146 restriction endonucleases Proteins 0.000 description 12
206010001233 Adenoma benign Diseases 0.000 description 11
101710197337 Adenovirus death protein Proteins 0.000 description 11
101000956263 Homo sapiens Uncharacterized protein C19orf48 Proteins 0.000 description 11
102100038573 Uncharacterized protein C19orf48 Human genes 0.000 description 11
-1 antisense molecule Proteins 0.000 description 11
208000029742 colonic neoplasm Diseases 0.000 description 11
230000000120 cytopathologic effect Effects 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 10
208000003200 Adenoma Diseases 0.000 description 10
201000003076 Angiosarcoma Diseases 0.000 description 10
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
208000001258 Hemangiosarcoma Diseases 0.000 description 10
208000018142 Leiomyosarcoma Diseases 0.000 description 10
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 10
206010061535 Ovarian neoplasm Diseases 0.000 description 10
108050002653 Retinoblastoma protein Proteins 0.000 description 10
102100038042 Retinoblastoma-associated protein Human genes 0.000 description 10
230000009471 action Effects 0.000 description 10
229960003094 belinostat Drugs 0.000 description 10
NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 10
230000010261 cell growth Effects 0.000 description 10
INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 10
230000002458 infectious effect Effects 0.000 description 10
230000002441 reversible effect Effects 0.000 description 10
OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 10
108020005345 3' Untranslated Regions Proteins 0.000 description 9
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 9
206010009944 Colon cancer Diseases 0.000 description 9
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 9
102000040945 Transcription factor Human genes 0.000 description 9
108091023040 Transcription factor Proteins 0.000 description 9
229940100197 antimetabolite Drugs 0.000 description 9
239000002256 antimetabolite Substances 0.000 description 9
206010016629 fibroma Diseases 0.000 description 9
239000012528 membrane Substances 0.000 description 9
JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 8
JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 8
102000043966 ABC-type transporter activity proteins Human genes 0.000 description 8
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 8
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 8
102000001301 EGF receptor Human genes 0.000 description 8
108060006698 EGF receptor Proteins 0.000 description 8
JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 8
206010033128 Ovarian cancer Diseases 0.000 description 8
206010061902 Pancreatic neoplasm Diseases 0.000 description 8
230000000340 anti-metabolite Effects 0.000 description 8
108010082820 apicidin Proteins 0.000 description 8
229930186608 apicidin Natural products 0.000 description 8
229940127093 camptothecin Drugs 0.000 description 8
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 8
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 8
239000000835 fiber Substances 0.000 description 8
230000006698 induction Effects 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
238000009126 molecular therapy Methods 0.000 description 8
230000002018 overexpression Effects 0.000 description 8
201000002528 pancreatic cancer Diseases 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 7
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 7
101001030069 Homo sapiens Major vault protein Proteins 0.000 description 7
206010020843 Hyperthermia Diseases 0.000 description 7
102100038884 Major vault protein Human genes 0.000 description 7
101710170181 Metalloproteinase inhibitor Proteins 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
238000003556 assay Methods 0.000 description 7
108010006025 bovine growth hormone Proteins 0.000 description 7
238000003235 crystal violet staining Methods 0.000 description 7
229960005420 etoposide Drugs 0.000 description 7
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 7
230000036031 hyperthermia Effects 0.000 description 7
201000010260 leiomyoma Diseases 0.000 description 7
230000010534 mechanism of action Effects 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 7
229950009213 rubitecan Drugs 0.000 description 7
229960000303 topotecan Drugs 0.000 description 7
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 7
238000001890 transfection Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
108091012583 BCL2 Proteins 0.000 description 6
208000005243 Chondrosarcoma Diseases 0.000 description 6
102000048850 Neoplasm Genes Human genes 0.000 description 6
108700019961 Neoplasm Genes Proteins 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
229930012538 Paclitaxel Natural products 0.000 description 6
208000032839 leukemia Diseases 0.000 description 6
201000006512 mast cell neoplasm Diseases 0.000 description 6
208000006971 mastocytoma Diseases 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
239000003475 metalloproteinase inhibitor Substances 0.000 description 6
230000000174 oncolytic effect Effects 0.000 description 6
229960001592 paclitaxel Drugs 0.000 description 6
208000003154 papilloma Diseases 0.000 description 6
230000026731 phosphorylation Effects 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
208000023958 prostate neoplasm Diseases 0.000 description 6
230000003362 replicative effect Effects 0.000 description 6
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
230000005945 translocation Effects 0.000 description 6
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 5
102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 5
229940123587 Cell cycle inhibitor Drugs 0.000 description 5
102000010091 Cold shock domains Human genes 0.000 description 5
108050001774 Cold shock domains Proteins 0.000 description 5
108010093502 E2F Transcription Factors Proteins 0.000 description 5
102000001388 E2F Transcription Factors Human genes 0.000 description 5
108010070675 Glutathione transferase Proteins 0.000 description 5
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 5
101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 5
206010025323 Lymphomas Diseases 0.000 description 5
229940079156 Proteasome inhibitor Drugs 0.000 description 5
102100039120 Retinoblastoma-like protein 1 Human genes 0.000 description 5
108050002592 Retinoblastoma-like protein 1 Proteins 0.000 description 5
101710183280 Topoisomerase Proteins 0.000 description 5
108010049024 Viral Oncogene Proteins Proteins 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
230000032823 cell division Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
238000010276 construction Methods 0.000 description 5
239000013078 crystal Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
208000005017 glioblastoma Diseases 0.000 description 5
239000003966 growth inhibitor Substances 0.000 description 5
201000011066 hemangioma Diseases 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
229940126170 metalloproteinase inhibitor Drugs 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000003207 proteasome inhibitor Substances 0.000 description 5
238000011160 research Methods 0.000 description 5
201000009410 rhabdomyosarcoma Diseases 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000002103 transcriptional effect Effects 0.000 description 5
206010044412 transitional cell carcinoma Diseases 0.000 description 5
229930185603 trichostatin Natural products 0.000 description 5
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
208000002699 Digestive System Neoplasms Diseases 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
102100038885 Histone acetyltransferase p300 Human genes 0.000 description 4
206010024612 Lipoma Diseases 0.000 description 4
102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
108090000315 Protein Kinase C Proteins 0.000 description 4
102000003923 Protein Kinase C Human genes 0.000 description 4
241000714474 Rous sarcoma virus Species 0.000 description 4
230000018199 S phase Effects 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
102000013529 alpha-Fetoproteins Human genes 0.000 description 4
108010026331 alpha-Fetoproteins Proteins 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
210000000234 capsid Anatomy 0.000 description 4
230000006037 cell lysis Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
230000007547 defect Effects 0.000 description 4
235000021186 dishes Nutrition 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000004807 localization Effects 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
230000000394 mitotic effect Effects 0.000 description 4
208000007538 neurilemmoma Diseases 0.000 description 4
208000029974 neurofibrosarcoma Diseases 0.000 description 4
238000001668 nucleic acid synthesis Methods 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
208000010370 Adenoviridae Infections Diseases 0.000 description 3
108010087905 Adenovirus E1B Proteins Proteins 0.000 description 3
206010060931 Adenovirus infection Diseases 0.000 description 3
208000003174 Brain Neoplasms Diseases 0.000 description 3
206010057248 Cell death Diseases 0.000 description 3
108091062157 Cis-regulatory element Proteins 0.000 description 3
241000709687 Coxsackievirus Species 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010076525 DNA Repair Enzymes Proteins 0.000 description 3
229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 3
101150082674 E2 gene Proteins 0.000 description 3
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 3
208000032612 Glial tumor Diseases 0.000 description 3
206010018338 Glioma Diseases 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 3
206010029098 Neoplasm skin Diseases 0.000 description 3
201000004404 Neurofibroma Diseases 0.000 description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
201000000582 Retinoblastoma Diseases 0.000 description 3
208000000453 Skin Neoplasms Diseases 0.000 description 3
108091027076 Spiegelmer Proteins 0.000 description 3
108010017842 Telomerase Proteins 0.000 description 3
239000000365 Topoisomerase I Inhibitor Substances 0.000 description 3
102100038313 Transcription factor E2-alpha Human genes 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
208000011589 adenoviridae infectious disease Diseases 0.000 description 3
108010084938 adenovirus receptor Proteins 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
239000002870 angiogenesis inducing agent Substances 0.000 description 3
230000002424 anti-apoptotic effect Effects 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
229960004679 doxorubicin Drugs 0.000 description 3
201000011523 endocrine gland cancer Diseases 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
229940022353 herceptin Drugs 0.000 description 3
238000001794 hormone therapy Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
206010027191 meningioma Diseases 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000004882 non-tumor cell Anatomy 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
206010039667 schwannoma Diseases 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000013605 shuttle vector Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
231100000588 tumorigenic Toxicity 0.000 description 3
230000000381 tumorigenic effect Effects 0.000 description 3
108010022579 ATP dependent 26S protease Proteins 0.000 description 2
241000701242 Adenoviridae Species 0.000 description 2
102400000059 Arg-vasopressin Human genes 0.000 description 2
101800001144 Arg-vasopressin Proteins 0.000 description 2
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
206010004146 Basal cell carcinoma Diseases 0.000 description 2
102000051485 Bcl-2 family Human genes 0.000 description 2
108700038897 Bcl-2 family Proteins 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
101710163595 Chaperone protein DnaK Proteins 0.000 description 2
201000005262 Chondroma Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108090000257 Cyclin E Proteins 0.000 description 2
102000003909 Cyclin E Human genes 0.000 description 2
102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 2
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
108020003215 DNA Probes Proteins 0.000 description 2
102100033195 DNA ligase 4 Human genes 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 2
108050009340 Endothelin Proteins 0.000 description 2
102000002045 Endothelin Human genes 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
206010053717 Fibrous histiocytoma Diseases 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
208000007569 Giant Cell Tumors Diseases 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025219 Lymphangioma Diseases 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229930192392 Mitomycin Natural products 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
102000001938 Plasminogen Activators Human genes 0.000 description 2
108010001014 Plasminogen Activators Proteins 0.000 description 2
208000037062 Polyps Diseases 0.000 description 2
102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
239000013614 RNA sample Substances 0.000 description 2
208000034541 Rare lymphatic malformation Diseases 0.000 description 2
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
206010068771 Soft tissue neoplasm Diseases 0.000 description 2
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 2
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
229940123237 Taxane Drugs 0.000 description 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010062129 Tongue neoplasm Diseases 0.000 description 2
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
102000013532 Uroplakin II Human genes 0.000 description 2
108010065940 Uroplakin II Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
108700010877 adenoviridae proteins Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229940009456 adriamycin Drugs 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000002280 anti-androgenic effect Effects 0.000 description 2
229940046836 anti-estrogen Drugs 0.000 description 2
230000001833 anti-estrogenic effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000000051 antiandrogen Substances 0.000 description 2
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
208000021592 benign granular cell tumor Diseases 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229960003668 docetaxel Drugs 0.000 description 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
229940082789 erbitux Drugs 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
229960005167 everolimus Drugs 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
208000024519 eye neoplasm Diseases 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
201000000052 gastrinoma Diseases 0.000 description 2
239000000499 gel Substances 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
201000002222 hemangioblastoma Diseases 0.000 description 2
201000005787 hematologic cancer Diseases 0.000 description 2
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
201000000284 histiocytoma Diseases 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
229960002411 imatinib Drugs 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
206010024627 liposarcoma Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000025036 lymphosarcoma Diseases 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
201000008806 mesenchymal cell neoplasm Diseases 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
229960001156 mitoxantrone Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
201000010225 mixed cell type cancer Diseases 0.000 description 2
208000029638 mixed neoplasm Diseases 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000004130 myoblastoma Diseases 0.000 description 2
201000010762 nasal cavity neoplasm Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
208000025402 neoplasm of esophagus Diseases 0.000 description 2
201000008026 nephroblastoma Diseases 0.000 description 2
206010061311 nervous system neoplasm Diseases 0.000 description 2
239000002547 new drug Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
208000008798 osteoma Diseases 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
208000023974 pharynx neoplasm Diseases 0.000 description 2
229940127126 plasminogen activator Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000004853 protein function Effects 0.000 description 2
239000003909 protein kinase inhibitor Substances 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
238000009666 routine test Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
208000000649 small cell carcinoma Diseases 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
229960003787 sorafenib Drugs 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
229940063683 taxotere Drugs 0.000 description 2
229960000235 temsirolimus Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
108091007466 transmembrane glycoproteins Proteins 0.000 description 2
208000025421 tumor of uterus Diseases 0.000 description 2
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical group ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
206010001150 Adenocarcinoma gastric Diseases 0.000 description 1
108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
101710094856 Apoptin Proteins 0.000 description 1
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
201000011057 Breast sarcoma Diseases 0.000 description 1
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000000274 Carcinosarcoma Diseases 0.000 description 1
102000005483 Cell Cycle Proteins Human genes 0.000 description 1
108010031896 Cell Cycle Proteins Proteins 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
201000005171 Cystadenoma Diseases 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000011724 DNA Repair Enzymes Human genes 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
101100506443 Danio rerio helt gene Proteins 0.000 description 1
102100035784 Decorin Human genes 0.000 description 1
108090000738 Decorin Proteins 0.000 description 1
101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
101150005585 E3 gene Proteins 0.000 description 1
101150066038 E4 gene Proteins 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
101710128765 Enhancer of filamentation 1 Proteins 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
201000005231 Epithelioid sarcoma Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
208000004413 Eyelid Neoplasms Diseases 0.000 description 1
206010050497 Eyelid tumour Diseases 0.000 description 1
101150064015 FAS gene Proteins 0.000 description 1
102000015212 Fas Ligand Protein Human genes 0.000 description 1
108010039471 Fas Ligand Protein Proteins 0.000 description 1
208000007659 Fibroadenoma Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
230000010190 G1 phase Effects 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
102000018802 High Mobility Group Proteins Human genes 0.000 description 1
108010052512 High Mobility Group Proteins Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 1
101001109620 Homo sapiens Nucleolar and coiled-body phosphoprotein 1 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
208000006001 Hypothalamic Neoplasms Diseases 0.000 description 1
101710125507 Integrase/recombinase Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
208000009164 Islet Cell Adenoma Diseases 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
208000032420 Latent Infection Diseases 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 1
108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
206010048723 Multiple-drug resistance Diseases 0.000 description 1
101000762244 Mus musculus Cadherin-17 Proteins 0.000 description 1
101001026869 Mus musculus F-box/LRR-repeat protein 3 Proteins 0.000 description 1
101100506445 Mus musculus Helt gene Proteins 0.000 description 1
101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
102100022726 Nucleolar and coiled-body phosphoprotein 1 Human genes 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
206010061332 Paraganglion neoplasm Diseases 0.000 description 1
208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102100028588 Protein ZNRD2 Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000028391 RNA cap binding Human genes 0.000 description 1
108091000106 RNA cap binding Proteins 0.000 description 1
102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 1
108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
208000003274 Sertoli cell tumor Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
208000025194 Sweat Gland Neoplasms Diseases 0.000 description 1
206010042658 Sweat gland tumour Diseases 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
102100039094 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
108010006886 Vitrogen Proteins 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
201000001256 adenosarcoma Diseases 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000003149 breast fibroadenoma Diseases 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VGRSISYREBBIAL-UHFFFAOYSA-N doronine Natural products O1C(=O)C(C(Cl)C)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN(C)CCC1C2=O VGRSISYREBBIAL-UHFFFAOYSA-N 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
208000014616 embryonal neoplasm Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
201000005616 epidermal appendage tumor Diseases 0.000 description 1
208000010932 epithelial neoplasm Diseases 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000006355 external stress Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
208000028149 female reproductive system neoplasm Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
108090000237 interleukin-24 Proteins 0.000 description 1
102000003898 interleukin-24 Human genes 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
208000012166 male reproductive system neoplasm Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
230000002071 myeloproliferative effect Effects 0.000 description 1
230000011234 negative regulation of signal transduction Effects 0.000 description 1
208000025440 neoplasm of neck Diseases 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
244000309459 oncolytic virus Species 0.000 description 1
208000027500 optic nerve neoplasm Diseases 0.000 description 1
208000025303 orbit neoplasm Diseases 0.000 description 1
201000000890 orbital cancer Diseases 0.000 description 1
229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
208000007312 paraganglioma Diseases 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
210000004786 perivascular cell Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
238000005375 photometry Methods 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
108010049148 plastin Proteins 0.000 description 1
229930192033 plastin Natural products 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000017610 release of virus from host Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000010485 smooth muscle tumor Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
230000004938 stress stimulation Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000027371 sweat gland benign neoplasm Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000010257 thawing Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
208000024363 trachea neoplasm Diseases 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000010415 tropism Effects 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
208000025444 tumor of salivary gland Diseases 0.000 description 1
239000000225 tumor suppressor protein Substances 0.000 description 1
108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 1
208000026517 ureter neoplasm Diseases 0.000 description 1
201000011476 ureteral benign neoplasm Diseases 0.000 description 1
208000024722 urethra neoplasm Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
210000003474 viral inclusion body Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2007548837A 2004-12-31 2006-01-02 動物細胞における多剤耐性を逆転させる方法 Active JP5584393B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE102004063639.7		2004-12-31
DE102004063639		2004-12-31
US65108505P	2005-02-08	2005-02-08
US60/651,085		2005-02-08
PCT/EP2006/000009 WO2006070023A2 (en)	2004-12-31	2006-01-02	Method for reversing multiple resistance in animal cells

Publications (3)

Publication Number	Publication Date
JP2008526188A JP2008526188A (ja)	2008-07-24
JP2008526188A5 JP2008526188A5 (zh)	2009-02-19
JP5584393B2 true JP5584393B2 (ja)	2014-09-03

Family

ID=36582063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007548837A Active JP5584393B2 (ja)	2004-12-31	2006-01-02	動物細胞における多剤耐性を逆転させる方法

Country Status (10)

Country	Link
US (4)	US20100310554A1 (zh)
EP (1)	EP1831382B1 (zh)
JP (1)	JP5584393B2 (zh)
KR (1)	KR101527213B1 (zh)
CN (1)	CN101128593B (zh)
AU (1)	AU2006203736B2 (zh)
CA (1)	CA2592699C (zh)
MX (1)	MX2007008136A (zh)
SG (1)	SG158133A1 (zh)
WO (1)	WO2006070023A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5213298B2 (ja)	2002-05-27	2013-06-19	ホルム，ペル・ゾンネ	アデノウイルスおよびそれをコードしている核酸の新たな使用
WO2005051430A1 (de)	2003-11-14	2005-06-09	Per Sonne Holm	Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1830864A2 (de) *	2004-12-31	2007-09-12	Per Sonne Holm	E1 -minus adenoviren und deren verwendung
US8691866B2 (en)	2008-12-10	2014-04-08	The General Hospital Corporation	HIF inhibitors and use thereof
SG10201604810UA (en) *	2012-02-07	2016-08-30	Global Bio Therapeutics Inc	Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP2971008B1 (en)	2013-03-14	2018-07-25	Salk Institute for Biological Studies	Oncolytic adenovirus compositions
CA2920667C (en)	2013-08-12	2023-02-21	Invivosciences Inc.	Automated system and method for culturing stem cells
JP7054527B2 (ja)	2016-02-23	2022-04-14	ソークインスティテュートフォーバイオロジカルスタディーズ	アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja)	2016-02-23	2022-02-15	ソークインスティテュートフォーバイオロジカルスタディーズ	ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
US10813957B2 (en) *	2016-10-07	2020-10-27	Miami University	Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
CA3045892A1 (en)	2016-12-12	2018-06-21	Salk Institute For Biological Studies	Tumor-targeting synthetic adenoviruses and uses thereof
CN110461323A (zh)	2017-03-31	2019-11-15	绪方久修	溶瘤病毒的增殖方法和抗肿瘤剂
MX2019014059A (es) *	2017-05-24	2020-07-28	Epicentrx Inc	Adenovirus antiangiogenico.
CN109576231B (zh) *	2017-09-28	2022-03-25	北京康万达医药科技有限公司	分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途
CN113774031B (zh) *	2020-06-10	2024-04-02	广州恩宝生物医药科技有限公司	一种复制型人腺病毒及其应用
WO2023054671A1 (ja) *	2021-09-30	2023-04-06	富士フイルム株式会社	アデノ随伴ウイルスの製造方法、細胞および発現ベクター

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3827163B2 (ja) *	1995-03-24	2006-09-27	ジェンザイム・コーポレーション	遺伝子治療用のアデノウイルスベクター
WO1997032481A1 (en) *	1996-03-07	1997-09-12	The Regents Of The University Of California	Helper-free, totally defective adenovirus for gene therapy
DE69903229T2 (de) *	1998-07-07	2003-06-26	Transgene Sa	Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression
WO2000029573A2 (en) *	1998-11-18	2000-05-25	Canji, Inc.	Adenoviral vectors
DE19929569A1 (de) *	1999-06-21	2000-12-28	Holm Per Sonne	Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
WO2001002556A2 (de) *	1999-06-30	2001-01-11	Max-Delbrück-Centrum für Molekulare Medizin	Mittel zur diagnose, prognose und therapie maligner erkrankungen
US6955808B2 (en) *	1999-09-24	2005-10-18	Uab Research Foundation	Capsid-modified recombinant adenovirus and methods of use
WO2001028569A1 (en) *	1999-10-15	2001-04-26	Canji, Inc.	Targeted vectors
US7048920B2 (en) *	2000-03-24	2006-05-23	Cell Genesys, Inc.	Recombinant oncolytic adenovirus for human melanoma
US20030095989A1 (en) *	2000-12-18	2003-05-22	Irving John M.	Chimeric cytolytic viruses for cancer treatment
EP1446479B1 (en) *	2001-09-29	2012-08-15	Chae-Ok Yun	Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
DE10150984A1 (de) *	2001-10-16	2003-04-17	Holm Per Sonne	Verwendung des adenoviralen E2-late-Promotors
US7285265B2 (en) *	2002-04-25	2007-10-23	Crucell Holland B.V.	Stable adenoviral vectors and methods for propagation thereof
JP5213298B2 (ja) *	2002-05-27	2013-06-19	ホルム，ペル・ゾンネ	アデノウイルスおよびそれをコードしている核酸の新たな使用
AU2003271730A1 (en) *	2002-10-15	2004-05-04	Per Sonne Holm	Novel adenoviruses, nucleic acids coding therefor, and use thereof
PL219321B1 (pl) *	2002-10-15	2015-04-30	Per Sonne Holm	Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
CA2522786A1 (en) *	2003-03-19	2004-09-30	Isogenis, Inc.	Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
JP4871726B2 (ja) *	2003-04-28	2012-02-08	ナノシス・インク．	超疎液性表面、その作製法及び用途
WO2005051430A1 (de) *	2003-11-14	2005-06-09	Per Sonne Holm	Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
CA2590257A1 (en) *	2003-11-14	2005-06-09	Per Sonne Holm	Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
EP1830864A2 (de) *	2004-12-31	2007-09-12	Per Sonne Holm	E1 -minus adenoviren und deren verwendung
US20070292396A1 (en) *	2006-03-02	2007-12-20	Juan Fueyo	Combination therapy with oncolytic adenovirus

2006
- 2006-01-02 CN CN200680006399.8A patent/CN101128593B/zh active Active
- 2006-01-02 JP JP2007548837A patent/JP5584393B2/ja active Active
- 2006-01-02 MX MX2007008136A patent/MX2007008136A/es active IP Right Grant
- 2006-01-02 AU AU2006203736A patent/AU2006203736B2/en active Active
- 2006-01-02 WO PCT/EP2006/000009 patent/WO2006070023A2/en active Application Filing
- 2006-01-02 KR KR1020077017703A patent/KR101527213B1/ko active IP Right Grant
- 2006-01-02 CA CA2592699A patent/CA2592699C/en active Active
- 2006-01-02 SG SG200908280-1A patent/SG158133A1/en unknown
- 2006-01-02 EP EP06701440.7A patent/EP1831382B1/en active Active
2009
- 2009-09-09 US US12/556,560 patent/US20100310554A1/en not_active Abandoned
2011
- 2011-06-28 US US13/170,395 patent/US20110286999A1/en not_active Abandoned
2017
- 2017-03-17 US US15/461,668 patent/US11369650B2/en active Active
2022
- 2022-05-24 US US17/752,436 patent/US20220339219A1/en active Pending

Also Published As

Publication number	Publication date
KR101527213B1 (ko)	2015-06-09
US11369650B2 (en)	2022-06-28
EP1831382A2 (en)	2007-09-12
US20110286999A1 (en)	2011-11-24
CA2592699A1 (en)	2006-07-06
AU2006203736A1 (en)	2006-07-06
SG158133A1 (en)	2010-01-29
CA2592699C (en)	2023-02-21
US20220339219A1 (en)	2022-10-27
WO2006070023A2 (en)	2006-07-06
KR20070103412A (ko)	2007-10-23
JP2008526188A (ja)	2008-07-24
WO2006070023A3 (en)	2006-09-21
AU2006203736B2 (en)	2012-03-29
MX2007008136A (es)	2008-02-12
CN101128593B (zh)	2014-09-03
US20170252443A1 (en)	2017-09-07
EP1831382B1 (en)	2023-01-18
CN101128593A (zh)	2008-02-20
US20100310554A1 (en)	2010-12-09

Legal Events

Date	Code	Title	Description
2008-12-23	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081222
2008-12-23	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081222
2011-07-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705
2011-09-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110905
2011-09-13	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110912
2012-01-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120105
2012-10-17	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121016
2012-12-07	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121206
2012-12-14	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121213
2013-04-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130416
2013-11-20	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131119
2014-03-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140319
2014-05-21	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140520
2014-06-19	TRDD	Decision of grant or rejection written
2014-06-25	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140624
2014-07-24	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140718
2014-07-25	R150	Certificate of patent or registration of utility model	Ref document number: 5584393 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2017-07-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-07-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-07-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-12-17	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-01-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-12-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-01-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-05-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
US20220339219A1 (en)	2022-10-27	Method for reversing multiple resistance in animal cells
JP5618896B2 (ja)	2014-11-05	新規アデノウイルス、それをコードする核酸及びその使用
JP5873893B2 (ja)	2016-03-01	アデノウイルスおよびそれをコードしている核酸の新たな使用
JP5435871B2 (ja)	2014-03-05	Ｅ１−マイナスアデノウイルス及びその使用
AU2010257327B2 (en)	2011-09-29	Adenovirus expressing genes in reverse order and use thereof
KR101123510B1 (ko)	2012-04-12	신규한 아데노바이러스, 이를 암호화하는 핵산 및 이들의 조성물